open access
Breast-conserving surgeries in HER-positive breast cancer patients are performed too rarely in Poland
, 34, 5, 6, 4, 6, 6, 7, 8, 9, 101112
Affiliations- Department and Chair of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland
- Chemotherapy Department, Greater Poland Cancer Centre, Poznan, Poland
- Department of Oncology, Institute of Medical Sciences, University of Opole, Poland
- Department of Clinical Oncology, Tadeusz Koszarowski Cancer Center in Opole, Opole, Poland
- Oncology Clinical Department, Krakow University Hospital , Krakow, Poland
- Breast Cancer and Reconstruction Surgery Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- Clinical Oncology Department with Outpatient Chemotherapy Sub-department of the Maria Skłodowska-Curie Bialystok Oncology Centre, Bialystok, Poland
- Oncology Department with Haematology Sub-department, Dr Roman Ostrzycki Voivodeship Hospital in Konin, Poland
- Roche Polska Sp. z o. o.
- General, Oncological and Vascular Surgery Clinic, 5th Military Hospital with a Polyclinic, Krakow, Poland
- Chair of Surgery, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University , Krakow, Poland
- Scientific Editors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
open access
Abstract
Breast cancer is the most common cancer among women in Poland and worldwide; after lung cancer it is the second highest cause of death among females with malignancies. HER2 positive breast cancer occurs in ca.15–20% of all cases. More often than other subtypes, it affects younger patients and more often spreads metastasises to internal organs.
The new drugs against the HER2 receptor significantly improve patients’ prognoses, regardless of the initial stage. The authors of the study involved 1503 patients with HER2 positive breast cancer from all stages (I–IV); 482 patients received preoperative systemic therapy (chemotherapy or hormonal therapy), 385 trastuzumab. Among the 1219 females qualified to surgery, 734 (60%) underwent a mastectomy, 485 (40%) had breast conserving therapy with adjuvant radiotherapy, some of them had preoperative systemic treatment.
Abstract
Breast cancer is the most common cancer among women in Poland and worldwide; after lung cancer it is the second highest cause of death among females with malignancies. HER2 positive breast cancer occurs in ca.15–20% of all cases. More often than other subtypes, it affects younger patients and more often spreads metastasises to internal organs.
The new drugs against the HER2 receptor significantly improve patients’ prognoses, regardless of the initial stage. The authors of the study involved 1503 patients with HER2 positive breast cancer from all stages (I–IV); 482 patients received preoperative systemic therapy (chemotherapy or hormonal therapy), 385 trastuzumab. Among the 1219 females qualified to surgery, 734 (60%) underwent a mastectomy, 485 (40%) had breast conserving therapy with adjuvant radiotherapy, some of them had preoperative systemic treatment.
Keywords
breast cancer; HER2 positive breast cancer; surgery; mastectomy; breast conserving therapy
About this articleTitle
Breast-conserving surgeries in HER-positive breast cancer patients are performed too rarely in Poland
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Research paper (original)
Pages
225-229
Published online
2020-12-04
Page views
647
Article views/downloads
615
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2020;70(6):225-229.
Keywords
breast cancer
HER2 positive breast cancer
surgery
mastectomy
breast conserving therapy
Authors
Joanna Kufel-Grabowska
Barbara Radecka
Joanna Streb
Agnieszka Jagiełło-Gruszfeld
Joanna Hudała-Klecha
Ewa Szombara
Renata Sienkiewicz
Bogumiła Czartoryska-Arłukowicz
Piotr Witasik
Katarzyna Sokołowska
Wojciech Wysocki
References (10)- Tao Z, Shi A, Lu C, et al. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys. 2014; 72(2): 333–338.
- Cronin KA, Harlan LC, Dodd KW, et al. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010; 28(9): 963–968.
- Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17(6): 791–800.
- PTBR Sm, Mikułowska M, Komorowska A, Falkiewicz B. Gryglewicz J. Rak piersi w Polsce – leczenie to inwestycja. Sequence, Uczelnia Łazarskiego, Warszawa 2014.
- Tan MP. Is there an Ideal Breast Conservation Rate for the Treatment of Breast Cancer? Ann Surg Oncol. 2016; 23(9): 2825–2831.
- Cardoso F, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30(10): 1674.
- Salindera S, Ogilvy M, Spillane A. What are the appropriate thresholds for High Quality Performance Indicators for breast surgery in Australia and New Zealand? Breast. 2020; 51: 94–101.
- Herman K, Śliwczyński A, Wysocki W. Wyniki, metody i koszty leczenia raka piersi w Polsce (w latach 2005–2007). Nowotwory. Journal of Oncology. 2014; 64(1): 33–39.
- Valachis A, Mauri D, Polyzos NP, et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast. 2011; 20(6): 485–490.
- Mamtani A, Morrow M. Why Are There So Many Mastectomies in the United States? Annu Rev Med. 2017; 68: 229–241.